These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Expression and purification of active receptor interacting protein 1 kinase using a baculovirus system. Maki JL; Tres Brazell J; Teng X; Cuny GD; Degterev A Protein Expr Purif; 2013 Jun; 89(2):156-61. PubMed ID: 23523699 [TBL] [Abstract][Full Text] [Related]
26. Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling. Tong Y; Stewart KD; Thomas S; Przytulinska M; Johnson EF; Klinghofer V; Leverson J; McCall O; Soni NB; Luo Y; Lin NH; Sowin TJ; Giranda VL; Penning TD Bioorg Med Chem Lett; 2008 Oct; 18(19):5206-8. PubMed ID: 18790640 [TBL] [Abstract][Full Text] [Related]
27. Identification and further development of potent TBK1 inhibitors. Richters A; Basu D; Engel J; Ercanoglu MS; Balke-Want H; Tesch R; Thomas RK; Rauh D ACS Chem Biol; 2015 Jan; 10(1):289-98. PubMed ID: 25540906 [TBL] [Abstract][Full Text] [Related]
28. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases. Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814 [TBL] [Abstract][Full Text] [Related]
29. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644 [TBL] [Abstract][Full Text] [Related]
30. Small-Molecule Receptor-Interacting Protein 1 (RIP1) Inhibitors as Therapeutic Agents for Multifaceted Diseases: Current Medicinal Chemistry Insights and Emerging Opportunities. Shi K; Zhang J; Zhou E; Wang J; Wang Y J Med Chem; 2022 Nov; 65(22):14971-14999. PubMed ID: 36346971 [TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and selection of DNA-encoded small-molecule libraries. Clark MA; Acharya RA; Arico-Muendel CC; Belyanskaya SL; Benjamin DR; Carlson NR; Centrella PA; Chiu CH; Creaser SP; Cuozzo JW; Davie CP; Ding Y; Franklin GJ; Franzen KD; Gefter ML; Hale SP; Hansen NJ; Israel DI; Jiang J; Kavarana MJ; Kelley MS; Kollmann CS; Li F; Lind K; Mataruse S; Medeiros PF; Messer JA; Myers P; O'Keefe H; Oliff MC; Rise CE; Satz AL; Skinner SR; Svendsen JL; Tang L; van Vloten K; Wagner RW; Yao G; Zhao B; Morgan BA Nat Chem Biol; 2009 Sep; 5(9):647-54. PubMed ID: 19648931 [TBL] [Abstract][Full Text] [Related]
32. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90. Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612 [TBL] [Abstract][Full Text] [Related]
33. Identification of an antibody-based immunoassay for measuring direct target binding of RIPK1 inhibitors in cells and tissues. Finger JN; Brusq JM; Campobasso N; Cook MN; Deutsch J; Haag H; Harris PA; Jenkins EL; Joglekar D; Lich JD; Maguire S; Nagilla R; Rivera EJ; Sun H; Votta BJ; Bertin J; Gough PJ Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226625 [TBL] [Abstract][Full Text] [Related]
34. 2,5-Diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of glycogen synthase kinase-3 (GSK-3). Lum C; Kahl J; Kessler L; Kucharski J; Lundström J; Miller S; Nakanishi H; Pei Y; Pryor K; Roberts E; Sebo L; Sullivan R; Urban J; Wang Z Bioorg Med Chem Lett; 2008 Jun; 18(12):3578-81. PubMed ID: 18502127 [TBL] [Abstract][Full Text] [Related]
35. Discovery of 3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one derivatives as a new class of ROCK inhibitors for the treatment of glaucoma. Sun Y; Li Y; Miao Z; Yang R; Zhang Y; Wu M; Lin G; Li L Bioorg Med Chem Lett; 2021 Aug; 45():128138. PubMed ID: 34044123 [TBL] [Abstract][Full Text] [Related]
37. Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model. Sato M; Kondo T; Kohno Y; Seto S Bioorg Med Chem; 2021 Mar; 34():116015. PubMed ID: 33549905 [TBL] [Abstract][Full Text] [Related]
38. Structure-based optimization of potent PDK1 inhibitors. Angiolini M; Banfi P; Casale E; Casuscelli F; Fiorelli C; Saccardo MB; Silvagni M; Zuccotto F Bioorg Med Chem Lett; 2010 Jul; 20(14):4095-9. PubMed ID: 20621725 [TBL] [Abstract][Full Text] [Related]
39. Design and synthesis of phenylisoxazole derivatives as novel human acrosin inhibitors. Zhao J; Tian W; Qi J; Lv D; Liu Y; Jiang Y; Dong G; Chen Q; Zhou Y; Zhu J; Wang H; Sheng C; Lv J Bioorg Med Chem Lett; 2014 Jul; 24(13):2802-6. PubMed ID: 24835199 [TBL] [Abstract][Full Text] [Related]
40. Discovery and SAR study of c-Met kinase inhibitors bearing an 3-amino-benzo[d]isoxazole or 3-aminoindazole scaffold. Jiang X; Liu H; Song Z; Peng X; Ji Y; Yao Q; Geng M; Ai J; Zhang A Bioorg Med Chem; 2015 Feb; 23(3):564-78. PubMed ID: 25537530 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]